(UroToday.com) Metformin is a biguanide agent which is commonly used in the first-line treatment of patients with type 2 diabetes. For many years, there has been an interest in its potential anti-cancer properties, particularly in prostate cancer. In observational studies, there has been a demonstrated association between the use of metformin and improved overall survival and reduction in the risk of developing castration-resistant disease.